1 INTRODUCTION Dravet syndrome (DS) is a rare epileptic encephalopathy characterized by drug-resistant epilepsy and neurodevelopmental problems.1 Fortunately, three antiseizure medications (ASMs) have received FDA approval, since 2018, for DS treatment in the US: pharmaceutical-grade cannabidiol,2, 3 stiripentol,4, 5 and fenfluramine.6-10 All three treatments are well tolerated, with cannabidiol resulting in 40% reductions2, 3 and fenfluramine and stiripentol resulting in 70% reductions in...
